Immutep Limited
ASX: IMM.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marc Voigt
- Employees
- 19
- Headquarters
- Sydney, Australia
- IPO year
- 1988
- Market cap
- A$88.4M
- Website
- https://www.immutep.com
Loading IMM…
Loading profile data…Frequently asked questions about IMM
What does Immutep Limited (IMM.AX) do?
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-i...
Where does IMM.AX trade?
Immutep Limited (IMM.AX) trades on the Australian Securities Exchange.
What sector is IMM.AX in?
Immutep Limited (IMM.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immutep Limited?
Marc Voigt is the chief executive officer of Immutep Limited (IMM.AX).
Where is Immutep Limited headquartered?
Immutep Limited is headquartered in Australia.
Does IMM.AX pay a dividend?
Immutep Limited (IMM.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMM.AX go public?
Immutep Limited (IMM.AX) completed its initial public offering in 1988.